Beam Therapeutics Inc. (BMV:BEAM)

Mexico flag Mexico · Delayed Price · Currency is MXN
325.00
0.00 (0.00%)
At close: Aug 28, 2025
Market Cap29.98B
Revenue (ttm)1.14B
Net Income (ttm)-7.52B
Shares Outn/a
EPS (ttm)-84.68
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume85
Average Volume168
Open325.00
Previous Close325.00
Day's Range325.00 - 325.00
52-Week Range309.00 - 590.00
Betan/a
RSI36.24
Earnings DateAug 6, 2025

About Beam Therapeutics

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sic... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2017
Employees 483
Stock Exchange Mexican Stock Exchange
Ticker Symbol BEAM
Full Company Profile

Financial Performance

In 2024, Beam Therapeutics's revenue was $63.52 million, a decrease of -83.18% compared to the previous year's $377.71 million. Losses were -$376.74 million, 184.3% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.